article thumbnail

The top 5 pharma M&A deals of 2020

pharmaphorum

2020’s M&A activity hasn’t quite reached the heights of last year’s, where two pharma mega-mergers – BMS’ buyout of Celegne and AbbVie’s acquisition of Allergan – accounted for almost 40% of total M&A deal values. Here we take a look at the biggest mergers and acquisitions of 2020 and what they might mean for the companies involved.

article thumbnail

The end-of-life care conundrum

pharmaphorum

Over recent years, there has been a growing consensus that using chemotherapy and aggressive treatments towards the end-of-life should be avoided, where possible, due to the lower quality of life reported. Once no cure can be found for a patient’s condition, decisions must be made about what is the most suitable path forwards.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Sugemalimab plus chemo boosts lung cancer survival, trial reveals

pharmaphorum

EQRx’s GEMSTONE-302 study evaluated the efficacy and safety of the investigational anti-PD-L1 antibody, sugemalimab, in combination with chemotherapy as a first-line treatment for patients with stage four non-small cell lung cancer (NSCLC), versus using chemotherapy alone. In 2020, an estimated 2.2

article thumbnail

Leveraging innate cell engagers for lymphoma treatment

European Pharmaceutical Review

Finally, Andreas looks at the prospects for antibodies that target the innate immune system in treating both haematological malignancies and solid tumours. As a result, when the patient’s lymphoma relapses after treatment with chemotherapy, BV and CPIs, there are no effective treatment alternatives for these patients.

article thumbnail

Transforming oncology with antibody therapeutics

European Pharmaceutical Review

Amivantamab was the first bispecific monoclonal antibody (BsMAb) approved in the EU to treat advanced NSCLC with EGFR exon 20 insertion mutations post chemotherapy. Overall, the mechanisms of action for amivantamab include ligand blocking, receptor degradation, and immune cell-mediated activity. 2020; 19(10): 2044–56.

article thumbnail

Sobi gets EU nod for Doptelet in rare blood disorder ITP

pharmaphorum

Sweden’s Sobi has secured EU approval for Doptelet in primary chronic immune thrombocytopenia (ITP), an indication that the company expects to accelerate sales of the drug. According to some analysts it could catapult sales to several hundred million dollars a year, perhaps even broaching the $1 billion threshold.

article thumbnail

ESMO 2022: neoadjuvant or adjuvant immunotherapy for locally advanced cancers?

Pharmaceutical Technology

The advent of immune checkpoint inhibition has arguably been the greatest breakthrough for the treatment of metastatic solid tumours, with durable complete responses observed across multiple cancer types. In 2020, Keytruda was approved for previously untreated metastatic MSI-H/dMMR CRC, with the KEYNOTE-177 study demonstrating an 8.3-month